Key Technologies
Genesis has the ability and expertise to undertake a full spectrum of high quality discovery and development science, from target discovery through to in- vivo studies and clinical development. Activity is focused on oncology and immunology.
Some of Genesis’ key products include:
- siRNA therapeutics in development for solid tumours
- Zyrogen - the fifth member of the fibroblast growth factor receptor family (FGFR5) which is implicated in the development of autoimmune and bone disorders.
- MED-1 - a vaccine technology with therapeutic potential in tuberculosis
